Journal of the American Chemical Society · 2022 · 152 citations · 32 references
MedicineMedicinal ChemistryOncologyCancer PharmacologyDrug DiscoveryMolecular OncologyEnzyme InhibitionLigand BindingProtein-ligand BindingProtein-ligand InteractionsRas Family OncogenesTargeting LigandsAllele-specific TherapyCancer Targeting LigandsCrystal Structure AnalysisKras G12c InhibitionKras InhibitorsKras-targeted TherapyOncogenic Ras MutationsRas-targeted Therapies
hotspot mutants remains challenging. Here we report the discovery of covalent chemical ligands for the common oncogenic mutant K-Ras(G12R). These ligands bind in the Switch II pocket and irreversibly react with the mutant arginine residue. An X-ray crystal structure reveals an imidazolium condensation product formed between the α,β-diketoamide ligand and the ε- and η-nitrogens of arginine 12. Our results show that arginine residues can be selectively targeted with small molecule electrophiles despite their weak nucleophilicity and provide the basis for the development of mutant-specific therapies for K-Ras(G12R)-driven cancer.
32
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
J.M. Ostrem, Ulf Peters, Martin L. Sos et al. · Nature · 2013 · 2.5K citations · Full text
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes, Jingchuan Zhang, Lian‐Sheng Li et al. · Cell · 2018 · 1.2K citations · Full text